ATHE vs. MTEM, NCNA, CMMB, ADXN, GRTX, UPC, AEZS, GHSI, MBRX, and MIRA
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Molecular Templates (MTEM), NuCana (NCNA), Chemomab Therapeutics (CMMB), Addex Therapeutics (ADXN), Galera Therapeutics (GRTX), Universe Pharmaceuticals (UPC), Aeterna Zentaris (AEZS), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Molecular Templates (NASDAQ:MTEM) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Molecular Templates received 339 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 60.00% of users gave Alterity Therapeutics an outperform vote.
In the previous week, Molecular Templates had 4 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Molecular Templates and 1 mentions for Alterity Therapeutics. Molecular Templates' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.09 indicating that Alterity Therapeutics is being referred to more favorably in the news media.
Molecular Templates has higher revenue and earnings than Alterity Therapeutics.
Alterity Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 250.00%. Given Molecular Templates' higher probable upside, analysts plainly believe Alterity Therapeutics is more favorable than Molecular Templates.
95.5% of Molecular Templates shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 18.7% of Molecular Templates shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Molecular Templates has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
Alterity Therapeutics has a net margin of 0.00% compared to Alterity Therapeutics' net margin of -57.92%. Molecular Templates' return on equity of 0.00% beat Alterity Therapeutics' return on equity.
Summary
Alterity Therapeutics beats Molecular Templates on 8 of the 15 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
